Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | CCNA2 |
| Gene Name: | CCNA2 |
| Protein Full Name: | Cyclin-A2 |
| Alias: | CCN1; CCNA; CGA2; Cyclin A; Cyclin A2 |
| Mass (Da): | 48537 |
| Number AA: | 432 |
| UniProt ID: | P20248 |
| Locus ID: | 890 |
| COSMIC ID: | CCNA2 |
| Gene location on chromosome: | 4q25-q31 |
| Cancer protein type: | NA |
| Effect of cancer mutation on protein: | NA |
| Effect of active protein on cancer: | NA |
| Number of cancer specimens: | 20338 |
| Percent of cancer specimens with mutations: | 0.23 |
| Normal role description: | NA |
| Commentary on involvement of protein in cancer: | Note: Hepatitis B virus (HBV) integration leads to the disruption of the cyclin A gene, and the production of a stable hybrid HBV-cyclinA2 fusion protein with transcription being driven by the viral promoter, which contributes to tumorigenesis in hepatocellular carcinoma (40-80%) |